Aranesp(darbepoetin alfa)
Aranesp (darbepoetin alfa) is a protein pharmaceutical. Darbepoetin alfa was first approved as Aranesp on 2001-06-08. It is used to treat anemia in the USA. It has been approved in Europe to treat anemia, chronic kidney failure, and neoplasms.
Download report
Favorite
Events Timeline
Commercial
Clinical
Drug
Target
Variants
Financial
Trends
Safety
Events Timeline
5D
1M
3M
6M
YTD
1Y
2Y
5Y
Max
Events
FDA approval date
EMA approval date
Patent expiration date
Study first post date
Last update post date
Start date
Primary completion date
Completion date
Results first post date
Mock data
Subscribe for the real data
Subscribe for the real data
Commercial
Therapeutic Areas
Trade Name
FDA
EMA
Aranesp (discontinued: Aranesp)
Drug Products
FDA
EMA
Reference product - 351(a)
Reference product - 351(a)
Interchangeable product - 351(k)
Interchangeable product - 351(k)
Biosimilar product - 351(k)
Biosimilar product - 351(k)
Labels
FDA
EMA
Brand Name | Status | Last Update |
|---|---|---|
| aranesp | Biologic Licensing Application | 2024-05-21 |
Indications
FDA
EMA
Indication | Ontology | MeSH | ICD-10 |
|---|---|---|---|
| anemia | EFO_0004272 | D000740 | D64.9 |
Agency Specific
FDA
EMA
No data
Patent Expiration
No data
Clinical
Clinical Trials
231 clinical trials
View more details
Mock data
Subscribe for the real data
Subscribe for the real data
Indications Phases 4
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Anemia | D000740 | EFO_0004272 | D64.9 | 3 | 18 | 19 | 6 | 6 | 49 |
| Kidney diseases | D007674 | EFO_0003086 | N08 | 1 | — | 14 | 6 | 4 | 25 |
| Neoplasms | D009369 | — | C80 | 1 | 11 | 11 | 2 | 1 | 25 |
| Chronic renal insufficiency | D051436 | — | N18 | 1 | — | 12 | 4 | 4 | 21 |
| Chronic kidney failure | D007676 | EFO_0003884 | N18.6 | — | — | 1 | 3 | — | 4 |
| Renal insufficiency | D051437 | — | N19 | — | — | — | 4 | — | 4 |
| Colorectal neoplasms | D015179 | — | — | — | — | — | 1 | 1 | 2 |
| Hyperparathyroidism | D006961 | EFO_0008506 | E21.3 | — | — | — | 1 | — | 1 |
| Secondary hyperparathyroidism | D006962 | EFO_1001173 | — | — | — | — | 1 | — | 1 |
Indications Phases 3
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Lung neoplasms | D008175 | — | C34.90 | — | 2 | 3 | — | 1 | 6 |
| Heart failure | D006333 | EFO_0003144 | I50 | 1 | 3 | 2 | — | 1 | 6 |
| Myelodysplastic syndromes | D009190 | — | D46 | 1 | 2 | 3 | — | — | 5 |
| Preleukemia | D011289 | — | — | 1 | 2 | 3 | — | — | 5 |
| Breast neoplasms | D001943 | EFO_0003869 | C50 | — | 3 | 1 | — | 1 | 5 |
| Syndrome | D013577 | — | — | 1 | 2 | 2 | — | — | 4 |
| Prostatic neoplasms | D011471 | — | C61 | — | 2 | 1 | — | 1 | 3 |
| Hematologic neoplasms | D019337 | — | — | 1 | 2 | 1 | — | 1 | 3 |
| Lymphoma | D008223 | — | C85.9 | — | 1 | 2 | — | — | 3 |
| Non-small-cell lung carcinoma | D002289 | — | — | — | 1 | 1 | — | — | 2 |
Show 11 more
Indications Phases 2
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Carcinoma | D002277 | — | C80.0 | — | 1 | — | — | — | 1 |
| Female genital neoplasms | D005833 | — | — | — | 1 | — | — | — | 1 |
| B-cell chronic lymphocytic leukemia | D015451 | — | C91.1 | — | 1 | — | — | — | 1 |
Indications Phases 1
No data
Indications Without Phase
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Renal cell carcinoma | D002292 | EFO_0000376 | — | — | — | — | — | 1 | 1 |
| Ovarian neoplasms | D010051 | EFO_0003893 | C56 | — | — | — | — | 1 | 1 |
| Pancreatic neoplasms | D010190 | EFO_0003860 | C25 | — | — | — | — | 1 | 1 |
| Endometrial neoplasms | D016889 | EFO_0004230 | — | — | — | — | — | 1 | 1 |
| Stomach neoplasms | D013274 | EFO_0003897 | C16 | — | — | — | — | 1 | 1 |
| Esophageal neoplasms | D004938 | — | C15 | — | — | — | — | 1 | 1 |
| Urinary bladder neoplasms | D001749 | — | C67 | — | — | — | — | 1 | 1 |
| Kidney neoplasms | D007680 | EFO_0003865 | C64 | — | — | — | — | 1 | 1 |
| Cardiomyopathies | D009202 | EFO_0000318 | I42 | — | — | — | — | 1 | 1 |
| Diabetic retinopathy | D003930 | EFO_0003770 | — | — | — | — | — | 1 | 1 |
Show 1 more
Epidemiology
Epidemiological information for investigational and approved indications
View more details
Drug
General
| Drug common name | Darbepoetin alfa |
| INN | darbepoetin alfa |
| Description | Erythropoietin precursor (Epoetin) |
| Classification | Protein |
| Drug class | erythropoietins |
| Image (chem structure or protein) |  |
| Structure (InChI/SMILES or Protein Sequence) | — |
Identifiers
| PDB | — |
| CAS-ID | — |
| RxCUI | — |
| ChEMBL ID | CHEMBL1201566 |
| ChEBI ID | — |
| PubChem CID | — |
| DrugBank | DB00012 |
| UNII ID | 15UQ94PT4P (ChemIDplus, GSRS) |
Target
No data
Variants
No data
Financial
Revenue by drug
$
€
£
â‚£
Aranesp – Amgen
Mock data
Subscribe for the real data
Subscribe for the real data
Mock data
Subscribe for the real data
Subscribe for the real data
Tabular view
Estimated US medical usage
Darbepoetin alfa
Total medical expenditures per year (USD, in millions)
Mock data
Subscribe for the real data
Subscribe for the real data
Number of persons purchased
Mock data
Subscribe for the real data
Subscribe for the real data
Number of purchases
Mock data
Subscribe for the real data
Subscribe for the real data
Refill frequency
Mock data
Subscribe for the real data
Subscribe for the real data
Price per prescription (USD)
Mock data
Subscribe for the real data
Subscribe for the real data
Tabular view
Trends
PubMed Central
Top Terms for Disease or Syndrome:
Mock data
Subscribe for the real data
Subscribe for the real data
Additional graphs summarizing 4,904 documents
View more details
Safety
Black-box Warning
Black-box warning for: Aranesp
Adverse Events
Top Adverse Reactions
Mock data
Subscribe for the real data
Subscribe for the real data
42,866 adverse events reported
View more details
© 2020-2025 Collaborative Drug Discovery Inc. (CDD) | Terms of Use